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Dengue  virus  (DENV),  a member  of  the  Flaviviridae  family,  can  be transmitted  to  humans  through  the
bite  of  infected  Aedes  mosquitoes.  The  incidence  of dengue  has  increased  worldwide  over  the past  few
decades.  Inadequate  vector  control,  changing  global  ecology,  increased  urbanization,  and  faster  global
travel  are  factors  enhancing  the  rapid  spread  of  the  virus  and its  vector.  In  the  absence  of speciﬁc  antiviral
treatments,  the  search  for a safe  and effective  vaccine  grows  more  imperative.  Many  strategies  have
been utilized  to develop  dengue  vaccines.  Here,  we  demonstrate  the  immunogenic  properties  of a  novel
dengue  nanovaccine  (DNV),  composed  of  ultraviolet  radiation  (UV)-inactivated  DENV-2,  which  has  been
loaded into  the  nanoparticles  containing  chitosan/Mycobacterium  bovis  Bacillus  Calmette-Guerin  cell wall
components  (CS/BCG-NPs).  We  investigated  the  immunogenicity  of DNV  in  a Swiss  albino  mouse  model.
Inoculation  with  various  concentrations  of vaccine  (0.3, 1, 3 and 10 g/dose)  with  three  doses,  15-day
apart,  induced  strong  anti-dengue  IgM and  IgG  antibodies  in  the  mouse  serum  along  with  neutralizing
antibody  against  DENV-2  reference  strain  (16681),  a clinical-isolate  strain  (00745/10)  and  the  mouse-
adapted  New  Guinea-C  (NGC)  strain.  Cytokine  and chemokine  secretion  in the  serum  of DNV-immunized
mice  showed  elevated  levels  of  IFN-,  IL-2,  IL-5, IL-12p40,  IL-12p70,  IL-17,  eotaxin  and  RANTES,  all  of
which  have  varying  immune  functions.  Furthermore,  we  observed  a DNV  dose-dependent  increase  in the
frequencies  of IFN--producing  CD4+ and  CD8+ T cells after  in  vitro  stimulation  of nucleated  cells.  Based
on  these  ﬁndings,  DNV  has the  potential  to become  a candidate  dengue  vaccine.
d  by Publishe
. Introduction
Dengue virus (DENV), of the genus Flavivirus, family Flaviviridae,
an be grouped into four antigenically distinct serotypes (DENV
–4). DENV is transmitted to humans through the bite of DENV-
nfected Aedes aegypti and Aedes albopictus.  Natural DENV infections
re thought to induce lifelong protection against the infecting
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264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-NElsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
homologous serotype and short-term cross protection against het-
erologous serotypes. Recent estimates indicate that up to 390
million infections occur annually worldwide, with approximately
96 million symptomatic cases [1].
DENV infections generally present with a wide range of clinical
symptoms, varying from asymptomatic infection, to undifferenti-
ated dengue fever (DF), to dengue hemorrhagic fever (DHF), dengue
shock syndrome [2], or other severe forms of dengue [2]. The
mechanisms underlying severe dengue disease are believed to
be related to pathogenic manifestations of the immune response,
including antibody cross-reactivity to the vascular endothelium,
disease-enhancing antibodies, complement proteins and byprod-
ucts, and soluble mediators such as cytokines and chemokines [3].
How each of these elements contributes to disease pathology is
not clear. DHF and DSS occur in secondary heterologous DENV
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Composition of DNV. A constant amount of the BCG-CWCs adjuvant was  loaded into
CS-NPs by adsorption–mixing method. Varying amounts of UVI-DENV were loaded
by  adsorption–mixing method to form DNV.
Groups CS-NPs (g/ml) BCG-CWCs
(g/ml)
UVI-DENV
antigen
(g/ml)
Saline control – – –
Adjuvant 45 20 –
0.3 g of DNV 45 20 3
1 g of DNV 45 20 10T. Hunsawong et al. / V
nfection at a 15–80 fold higher frequency than in primary infection.
hese levels underscore the signiﬁcance of preexisting anti-DENV
ntibodies, which may  enhance infections by heterologous DENV
erotypes. There is no DENV-speciﬁc treatment available, increas-
ng the need for an effective vaccine that can provide simultaneous
rotection against all four serotypes with minimal reactogenicity.
urrently, there are no licensed dengue vaccines. However, there
re several vaccine candidates under development, all using differ-
nt strategies to provide protection. These include live-attenuated
accines [4–6], puriﬁed inactivated vaccines [7,8], recombinant
accines [9], chimeric vaccines [10], virus-like particles vaccines
11,12] and subunit vaccines [13,14]. Many of these are in pre-
linical and clinical trials. Vaccine development is hampered
y the complexity of the immune responses, the potential for
nterference when all four DENV serotypes are delivered simulta-
eously, and the theoretical safety risk of vaccine-related immune
nhancement.
Subunit and recombinant protein vaccines are thought to be
afer than live-attenuated vaccines since their composition is
evoid of replicative forms of the virus, usually associated with
eactogenicity. However, subunit and recombinant vaccines can
ail to elicit robust cell-mediated immune responses and are also
asily degraded by lysosomal enzymes [15,16]. The dengue/yellow
ever chimeric vaccine (CYD-TDV) is the most advanced candi-
ate dengue vaccine, currently in phase III clinical trials [17]. It
s unknown how the lack of DENV non-structural (NS) proteins,
 source of T cell epitopes, in the CYD-TDV will affect long-term
mmunogenicity and protection. Puriﬁed inactivated vaccines can
e done by several methods including heat-inactivation, chemi-
al inactivation and UV irradiation. Formalin inactivation is widely
sed in many vaccines such as polio virus, JEV, dengue and
nﬂuenza virus. It is known that formalin treatment destroys
mportant viral epitopes [18,19]. A more recent approach in vac-
ine development links DENV to the phosphoreactive psoralen,
′-aminomethyltrioxalen hydrochloride [20], which cross-links
yrimidine residues when exposed to UV-A radiation [21]. The
MT-UV inactivated virus freely penetrates the cell phospho-
ipid bilayer, while retaining intact structural and non-structural
pitopes. This approach may  increase the vaccine-induced cyto-
oxic T cell responses, similar to what has been reported for
S3[22].
Improving vaccine immunostimulatory properties may  require
he use of adjuvants and improved delivery systems. Nanotechnol-
gy is fast becoming a widely used approach for drug and vaccine
elivery. Several methods are used to generate nanoparticles (NPs)
ncluding coacervation [23], emulsion [24] and polymerization
25]. Because of their small size, NPs easily cross the blood brain
arrier and access the interior of cells and various intracellular
ompartments [26]. NPs stimulate antigen uptake by antigen-
resenting cells (APCs) [27], while reducing toxicity and other side
ffects associated with drugs [28,29]. In animal models, NPs have
een used to improve delivery and efﬁcacy of inﬂuenza [30–32]
nd hepatitis B vaccines [33,34], underscoring NPs applicability to
ther experimental vaccines. The cell wall components of Mycobac-
erium bovis Bacillus Calmette-Gurin (BCG-CWCs) are widely used
s adjuvant for several vaccine developments. BCG-CWCs serve
s a ligand for TLR2/4 that pasty share their signaling pathway
hrough MyD88, an adaptor that is essential for effective cytotoxic
 lymphocytes induction, and TIRAP, lead to the activation of NF-
B and productions of cytokine such as TNF, IL-1, IL-6, IL-8 and
hemokines like MIP  [35]. It has been reported that mice treated
.p. with BCG showed robust antigen presentation and increased
L-1, IL-6 and TNF production in peritoneal macrophages [36,37].
ince BCG-CWCs have the capability of modulating T cell responses,
S/BCG-NPs were used as an adjuvant and delivery system for DNV
n this study.3 g of DNV 45 20 30
10 g of DNV 45 20 100
Here, we report the ability of DNV, composed of AMT-
UV-inactivated whole DENV2 loaded chitosan (CS)/M. bovis
Bacillus Calmette-Guerin (BCG) cell wall components nanoparticles
(CS/BCG-NPs), to stimulate humoral and cellular immunogenicity
in a Swiss albino mouse model.
2. Materials and methods
2.1. Adjuvant preparation and vaccine formulation
CS/BCG-NPs were used as the adjuvant delivery carriers for
dengue nanovaccine (DNV). Preparation of the adjuvant was started
from chitosan core-shell nanoparticles synthesis by an emulsiﬁer-
free emulsion-polymerization method [38]. Cell wall components
of M. bovis BCG were isolated from heat-inactivated M.  bovis BCG
Tokyo 172 by French pressure cell press [39]. No toxicity was found
when the adjuvant was tested in primary human DCs, THP-1 cells
and LLC-MK2 cells (data not shown). The integrity of the component
was checked using an anti-lipoarabinomannan (LAM) antibody. The
antigenicity of the sucrose gradient-puriﬁed AMT-UV-inactivated
DENV-2 strain 16681 (UVI-DENV) [7,21,40] was  tested by typing
ELISA using 4G2, 3H5 and 2H2 monoclonal antibodies (data not
shown). Protein concentration was determined by bicinchoninic
acid (BCA) assay using bovine serum albumin as a standard (Bio-Rad
Laboratories, USA). The complete inactivation of the UVI-DENV-2
antigen was  veriﬁed by inoculating the antigen in LLC-MK2 cells
and incubating the cells 6 days, after which we were unable to
detect any plaque-forming units in the undiluted preparation (data
not shown).
To generate DNV, BCG and UVI-DENV were sequentially loaded
onto CS-NPs by an absorption-mixing method at 250 rpm for 16 h
[41]. A constant amount of adjuvant was used in all the groups of
immunized mice, except in the saline group (Table 1). DNV was
cleaned by centrifugation at 10,000 rpm for 1 h to remove unbound
components. Vaccine particle size and surface charge were deter-
mined by zetasizer (NanoZS 4700, Malvern Instruments, UK).
Loading efﬁcacy of UVI-DENV was determined by staining the DNV
with FITC-conjugated anti-ﬂavivirus antibodies. The frequency of
UVI-DENV present on NPs was  observed by BD LSRFortessaTM Cell
Analyzer (BD Biosciences, data not shown).
2.2. Animals
Adult female Swiss albino mice, Mus  musculus ICR outbred strain
aged 6 to 8 weeks and of 25–30 g of body weight were maintained
at the Department of Veterinary Medicine, United States Army
Medical Component-Armed Forces Research Institute of Medical
Sciences (USAMC-AFRIMS) (Bangkok, Thailand) under good animal
welfare conditions. All procedures involving mice were performed
in compliance with national laws and institutional policy and with
the permission of the AFRIMS Institutional Animal Care and Use
Committee.
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.3. Vaccine immunization
Seventy two mice were separated into six group (n = 12 per
roup) and i.p. vaccinated with three doses (100 l, 15 days apart)
f various vaccine formulations including saline as a negative con-
rol, adjuvant alone (CS/BCG-NPs) or DNV (0.3, 1, 3 and 10 g/dose).
lood was collected from each group of immunized mice (3 mice
er group in each time point) on days 0, 14, 16, 17, 29, 31, 32, 37,
4 and 58. Individual serum samples were used in each experi-
ent to determine the level of anti-DENV-1, -2, -3, -4 IgM/IgG
ntibodies, DENV-2 neutralizing antibody and cytokine/chemokine
roductions. Spleens were collected on days 29, 37, 44 and 58 to
nvestigate cell-mediated immune responses induced by DNV.
.4. Cytokine production
Collected serum samples were tested individually for the pres-
nce of interleukin (IL)-1,  IL-1, IL-2, IL-4, IL-5, IL-6, IL-10,
L-12p40, IL-12p70, IL-17, interferon (IFN)-,  G-CSF, GM-CSF, MCP-
, MIP-1,  MIP-1,  RANTES and TNF- using the bead-based
ultiplex Bio-Plex assay system (Bio-Rad Laboratories, USA) fol-
owing the manufacturer protocol. The assay was  performed
n triplicate wells. Brieﬂy, dye bead-coupled capture antibod-
es were incubated with standards or serum samples for 30 min
n an 800 rpm shaker at room temperature. Unbound material
as washed prior to incubation with biotinylated detection anti-
odies for 30 min  on an 800 rpm shaker at room temperature.
fter washing away unbound biotinylated antibodies, a reporter
treptavidin–phycoerythrin conjugate was added to the beads and
ncubated for 10 min  on an 800 rpm shaker at room tempera-
ure. After removing excess streptavidin–phycoerythrin, the bound
eads were counted via a dual laser ﬂow-based reader, which
easures the ﬂuorescence of the bound SA-PE in terms of mean
uorescence intensity (MFI).
.5. Cell-mediated immune response
Cell-mediated immune responses in individual PBMC’s were
etermined in three independent experiments (each in triplicates)
y measuring the frequencies of IFN- producing cells among
ntigen-stimulated CD4+ or CD8+ T cells. Splenocytes were seeded
nto a 24-well plate at a concentration of 2 × 106 cells/ml. Ten
g per well of DNV was added into the splenocytes to stimulate
FN- secretion. Cells were incubated at 37 ◦C for 48 h, harvested
nd stained with PE-conjugated rat anti-mouse CD4 (clone RM4-
, BD Biosciences, USA), and APC-conjugated rat anti-mouse CD8
clone 53-6.7, BD Biosciences). Cells were permeabilized with
D Cytoﬁx/CytopermTM (BD Biosciences) prior to staining with
ITC-conjugated anti-mouse IFN- (clone XMG1.2, BD Biosciences,
SA). The frequency of IFN- secreting cells was measured by BD
SRFortessaTM Cell Analyzer (BD Biosciences). Twenty-thousand
vents were collected to calculate the positive frequency.
.6. Anti-dengue IgM/IgG ELISA
Serum anti-DENV-2 IgM/IgG antibodies were measured by cap-
ure ELISA [42]. Brieﬂy, serum was diluted as 1:10 with PBS prior
o adding it into anti-mouse IgM or IgG-coated wells. One micro-
ram per well of UVI-DENV antigen was added followed by horse
adish peroxidase (HRP)-conjugated human anti-ﬂavivirus sec-
ndary antibody (Pooled human anti-ﬂavivirus antibody lot 21 Aug
3). Sureblue TMB  solution (KPL, Inc., USA), HRP substrate, was
dded. The reaction was stopped at 30 min  with 0.2 mM sulfuric
cid. 33 (2015) 1702–1710
For the detection of cross-reactive anti-DENV IgM/IgG anti-
bodies, we  used the same protocol as described above with the
exception of the antigen added to the wells. In this case, we used
pooled 16 HA units of DENV-1 (Hawaii, lot#08/02/48, 5120 HA
titer), 16 HA units of DENV-3 (1006 lot#08/02/48, 640HA titer) and
8 HA units of DENV-4 (H241, lot# 08 Jan 04, 640HA titer) antigens,
instead of the UVI-DENV antigen.
The optical density (OD) values were measured at 492 nm and
used to calculate the ELISA units using the following formula:
[(ODTest − ODNegative control)/(ODPositive control − ODNegative control)] ×
100. The results from three independent experiments testing
individual samples (each in duplicates) were used to calculate the
mean ELISA units in each group.
2.7. Dengue neutralizing antibody
To determine the immunogenicity of DNV, we measured
vaccine-induced neutralizing (NT) antibodies in each individual
serum sample against DENV-2 reference strain (16681), a clinical-
isolate strain (00745/10) and the mouse-adapted strain (NGC) [43]
by plaque reduction neutralization test (PRNT50) [44]. The assay
was done in three independent experiments (in duplicates). Serum
was diluted in a four-fold serial dilution and mixed with the virus
in equal volumes before incubation in a 35 ◦C water bath for 1 h.
The mixture was inoculated into Rhesus monkey kidney epithe-
lial cell (LLC-MK2 cells) in a 12-well plate and incubated at RT for
1 h on a rocker platform. The excess volume of the inoculum was
removed. First medium over layer containing low melting point
agarose gel (LMP, Ultra PureTM LMP  agarose, Invitrogen, USA) was
added. DENV-infected cells were incubated for 6 days in a 5% CO2
incubator at 35 ◦C before staining with 4% neutral red (Sigma, USA)
in a second medium over layer with LMP. The number of plaques
was determined by manual counting. NT antibody titer was cal-
culated by SPSS program, using regression with probit analysis at
50% reduction which was  identiﬁed as the highest dilution that can
reduce the number of plaques by 50% as compared to the number
of plaques in virus control well.
2.8. Statistical analysis
Mann–Whitney U test/Kruskal–Wallis analysis was used to
compare the difference of anti-dengue IgM/IgG antibodies, neu-
tralizing antibodies, and cytokine/chemokine production among
control and other groups. A p-value of less than 0.05 was considered
statistically signiﬁcant. Descriptive statistical analysis was used to
describe the basic features of cell-mediated immunity (CMI) [45].
3. Results
DNV was  shown to be spherical in shape with a diameter of
372 ± 11 nm, and polydispersity index of 0.227–0.254, indicating
narrow size distribution. Its zetapotential was +20.6 mV,  referring
to cationic surface.
3.1. Cytokine production
We  measured 18 different cytokines in the serum of vaccinated
mice at designated times. We  categorized these cytokines into ﬁve
groups including: proinﬂammatory cytokines (IL-1, IL-1, IL-6, IL-
17 and TNF-), Th1 cytokines (IFN-, IL-2, IL-12p40 and IL-12p70),
Th2 cytokines (IL-4, IL-5 and IL-10), chemokines (MCP-1, MIP-1,
MIP-1  and RANTES), and growth factors (G–CSF and GM–CSF).
These are shown as heat maps in Fig. 1. More detailed data are
presented in graphs in Suppl. Fig. 1.
Mouse groups receiving the CS/BCG-NP adjuvant had higher lev-
els of proinﬂammatory cytokines in their serum than the saline
T. Hunsawong et al. / Vaccine 33 (2015) 1702–1710 1705
Fig. 1. Cytokines/chemokines production in the serum of saline, adjuvant and various concentrations of DNV-immunized mice (0.3, 1, 3 and 10 g) were determined by
b Th1 ty
i
g
t
a
b
sioplex assay. All cytokines were categorized into pro-inﬂammatory cytokines (A), 
n  the mean value (n = 3) of each cytokines at a designated time points.
roup (Fig. 1A, Suppl. Fig. 1). In particular, while there was lit-
le IL-1 generated other than in the group receiving adjuvant
lone, IL-1 in the DNV-inoculated groups (all doses) was  present
y day 14 and stably produced until day 58 at levels that were
igniﬁcantly higher than in the saline or adjuvant group (p-valuepe cytokines (B), Th2 type cytokines (C) and chemokines (D). The results presented
<0.05, suppl. Fig. 1). TNF- production was more transient, with
signiﬁcantly higher levels being detected in the DNV-inoculated
groups (all doses) by day 14 (p-value <0.05, Suppl. Fig. 1). IL-6 was
detected only at very low concentrations in the serum (2–10 pg/ml).
Nonetheless, we  were able to detect a signiﬁcant increase of IL-6 in
1706 T. Hunsawong et al. / Vaccine 33 (2015) 1702–1710
Fig. 2. Cellular immune responses induced by DNV. Splenocytes collected from saline, adjuvant and various concentration of DNV 0.3, 1. 3 and 10 g/dose immunized mice
were  stimulated with 10 g of DNV prior to staining of CD4 (A), CD8 (B) and IFN.( saline, adjuvant, DNV 0.3 g, DNV 1 g, DNV 3 g, DNV
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w0  g). a Indicates signiﬁcant differences between adjuvant and saline, * Indicates si
igniﬁcant differences between saline/adjuvant and various concentrations of DNV
he 1 g DNV group at days 31, 37 and 58 above all other groups.
djuvant alone was a signiﬁcant inducer of IL-17 at various time
oints.
IFN- and IL-2 appeared to be the only Th1-associated cytokines
nduced by DNV, albeit at very low concentrations (Fig. 1B, Suppl.
ig. 1). Levels of IFN- were signiﬁcantly higher in all DNV-
accinated groups by day 37 (7 days post dose three) and continued
o until day 58, as compared with the adjuvant and saline groups (p-
alue <0.05, Suppl. Fig. 1), although some DNV-vaccinated groups
enerated higher levels of IFN- by day 14. Levels of IL-2 were only
etectable at signiﬁcant (p-value <0.05, suppl. Fig. 1) levels above
he adjuvant and saline groups on days 31 to 44, although not con-
istently in all DNV-vaccinated groups. There is little evidence that
NV induced secretion of IL-12p40 and IL-12p70 in mice, with most
f these cytokines generated by the adjuvant alone.
We were able to detect a sharp spike in the secretion of the
h2-associated cytokine IL-5 in the serum of DNV-inoculated mice
all doses) by day 31 (1 day post dose 3), although levels normal-
zed soon afterward (Fig. 1C, Suppl. Fig. 1). We  measured other Th2
ytokines (IL-4 and IL-10), with little evidence that DNV induced
etectable levels of either of them. DNV induction of IL-10 may  be
ttributable to the adjuvant alone.
Production of the chemokines MIP-1,  MIP-1,  MCP-1, RANTES
nd eotaxin varied (Fig. 1D, Suppl. Fig. 1). MCP-1 production was
etected at levels signiﬁcantly higher above the adjuvant and saline
roups (p-value <0.05, Suppl. Fig. 1) as early as day 14 (0.3 g DNV
roup) and continued until day 58 for most DNV-vaccinated groups.
nterestingly, MCP-1 was lower at the highest DNV doses. DNV-
nduced MIP-1 secretion above the adjuvant and saline groups
as most signiﬁcant on days 37 (7 days post dose 3) and 58nt differences between 10 g of DNV and other concentrations of DNV, ** indicates
(p-value <0.05, Suppl. Fig. 1), although one low DNV  dose group
(1 g DNV) induced the highest levels of MIP-1  by days 31 and
32 (1 and 2 days post dose 3). We  found a similar pattern for the
induction of RANTES, with all DNV-inoculated groups secreting sig-
niﬁcant levels (p-value <0.05) above the adjuvant and saline groups
by days 31 and 32 (1 and 2 days post dose 3) which then contin-
ued until day 44 and normalizing by day 58. Induction of MIP-1
in the DNV-inoculated groups was  evident on day 14 (14 days post
dose 1), and were higher than the adjuvant and saline groups (p-
value <0.05, suppl. Fig. 1). Other cytokines investigated included
the growth factors, G–CSF and GM–CSF, of which there were no
evidence of induction in our experiments.
3.2. Cell-mediated immune response
We  measured DNV cell-mediated immune responses by the
frequency of CD4+ IFN+ or CD8+ IFN+ T cells after in vitro stim-
ulation with 10 g of DNV for 48 h (Fig. 2). Mice were inoculated
(3 doses, 15 days apart) with saline or DNV at different concentra-
tions (0.3, 1, 3 or 10 g per dose). Spleens were collected at various
times and used for splenocyte isolation. Flow cytometry revealed
higher frequencies of CD4+ IFN+ and CD8+ IFN+ T cells collected
from the adjuvant and vaccine immunized mice. The group vac-
cinated with 10 g of DNV generated the highest frequency of
CD4+/IFN+ T cells (4.35%, 6.13%, 2.48% and 1.40% for days 29, 37,
44 and 58, respectively) and CD8+/IFN+ T cells (1.38%, 0.61%, 1.11%
and 0.48% for days 29, 37, 44 and 58, respectively) throughout the
length of the experiment. Inoculation with DNV at 3 and 10 g
per dose generated frequencies of CD4+/IFN+ T cells signiﬁcantly
higher (p < 0.05) than any other group on days 29 and 37. Similarly,
T. Hunsawong et al. / Vaccine 33 (2015) 1702–1710 1707
Fig. 3. Mice were immunized with saline, adjuvant or various concentrations of DNV (0.3, 1, 3 and 10 g) for three doses (15-day apart), blood was collected at designated time
points to determine the level of anti-DENV2 IgM antibodies (A), anti-DENV2 IgG antibodies (B), anti-DENV1, 3, 4 IgM antibodies (C) and anti-DENV1, 3, 4 IgG antibodies (D) by
capture ELISA.( Saline, Adjuvant, DNV 0.3 g, DNV 1 g, DNV 3 g, DNV 10 g). a Indicates signiﬁcant differences between adjuvant and placebo,
*  conc
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e indicates signiﬁcant differences between saline/adjuvant/0.3 g of DNV and other
arious concentrations of DNV, *** indicates signiﬁcant differences between 0.3 g/
NV  with other groups, ***** indicates signiﬁcant differences among 3 g of DNV w
noculation with DNV at the highest doses (in particular 10 g) gen-
rated CD8+/IFN+ T cells at frequencies that were higher than the
djuvant and saline groups on days 29, 37 and 44.
.3. Anti-dengue IgM/IgG ELISA
We  tested the ability of DNV to generate antigen-speciﬁc IgM
nd IgG antibodies using an ELISA method. Mice were inoculated
3 doses, 15 days apart) with saline or DNV at different concen-
rations (0.3, 1, 3 or 10 g per dose). Anti-DENV-2 IgM antibodies
ere detected in all DNV vaccinated groups on day 17 (two days
ost dose 1), day 37 (7 days post dose 3) and day 44 (14 days post
ose 3) at levels that were signiﬁcantly higher (p-value <0.05) than
he saline or adjuvant groups (Fig. 3A). As expected, IgM antibod-
es were induced in a dose-dependent manner. Peak IgM levels
ere 60.4 ± 4.9 and 67.3 ± 5.0 ELISA units for 3 g and 10 g of
NV, respectively, while immunization with 0.3 g and 1 g of
NV induced peak IgM levels of 24 ± 14.0 and 24 ± 9.2 ELISA units,
espectively, on day 37. Differences among the DNV-inoculated
roups were not detectable by day 44.
Serum anti-DENV2 IgG antibodies were also detected in all vac-
inated groups in a dose-dependent manner (Fig. 3B), with the two
ighest dose-groups generating signiﬁcantly higher levels of IgG as
arly as day 16 (p-value <0.05) and the group receiving 10 g perentrations of DNV, ** indicates signiﬁcant differences between saline/adjuvant and
f DNV and 3 g/10 g of DNV, **** indicates signiﬁcant differences among 10 g of
her groups.
dose generating higher IgG levels (p-value <0.05) as early as day
14 (two weeks post dose 1). IgG levels gradually increased until
day 58 for all vaccine doses. All DNV vaccinated groups except the
0.3 g DNV group generated levels of IgG from day 29 to day 58
which were signiﬁcantly higher (p-value <0.05) than in the saline
and adjuvant groups. Production of IgG peaked on days 37 and 44
which were 7 and 14 days after the third vaccine dose.
We investigated the generation of cross-reactive antibodies in
the serum using pooled DENV-1, -3 and -4 antigens in an ELISA
format. IgM cross-reactivity in the DNV-immunized groups was
evident by day 29 and continued until day 58. These levels were
nonetheless lower than those found in ELISA using DENV-2 as anti-
gen (Fig. 3A). Cross-reactive anti-DENV IgM antibodies in the 3 and
10 g DNV immunized mice were signiﬁcant higher than other
DNV dose groups on day 37 (p-value = 0.03 and 0.03 for 3 and 10 g
of DNV, respectively) and 44 (p-value = 0.002 and 0.002 for 3 and
10 g of DNV, respectively). We  detected similar trends for IgG
antibody production (Fig. 3D).
3.4. Dengue neutralizing antibodyVaccine-induced neutralizing antibody levels against DENV2
reference strain (16681), a clinical-isolate strain (00745/10) and
the mouse-adapted NGC strain [43] were determined by plaque
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Fig. 4. Neutralizing antibody titer determined by PRNT50 against DENV-2 reference strain (16681), clinical isolated strain (00745/10) and mouse adapted strain (NGC) in the
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ierum of saline control (NC), adjuvant and various concentrations (0.3, 1, 3 and 10
etween 10 g of DNV and other concentrations of DNV.
eduction neutralization test (PRNT50) on serum collected on days
, 29, 37, 44 and 58. The results are summarized in Fig. 4. There
ere no NT antibodies in the saline (NC) group, and only very low
evels in the adjuvant group against the DENV-2 reference strain
16681) on days 29 and 44. Overall, generation on NT antibod-
es against the clinical isolate 00745/10 was lowest across all days
nd DNV groups. In the DNV groups, NT antibodies against DENV-
 16681 and NGC were detected on day 29 and throughout the
xperiment. NT titers against DENV-2 00745/10 were lower in all
NV groups. DNV-immunized mice showed signiﬁcant higher of
T titers than saline and adjuvant group only on days 44 and 58.
e  also found that DNV-induced NT antibodies against DENV-2
6681 and 00745/10 were produced in a dose-dependent manner
n days 29, 37 and 58 and against the NGC strain on day 44. DNV at
0 g was the only dose capable of stimulating signiﬁcantly higher
iters of NT antibodies against all three DENV-2 viruses (day 44,
 < 0.05). We  observed varying levels of NT antibodies among the
hree DENV2 strains used in the PRNT, but consistent within each
RNT strain. The results also indicated that mice vaccinated with
, 3 or 10 g/dose consistently yielded titers that were higher than
he control groups throughout the length of the study.. Discussion
Dengue virus poses a signiﬁcant public health problem affect-
ng a large segment of the world population. An effective and safef DNV immunized mice at day 29, 37, 44 and 58.* Indicates signiﬁcant differences
dengue vaccine is required to control the spread of DENV. Sev-
eral prototypic dengue vaccines have been tested over the years,
each using different development strategies. Recently, the live-
attenuated tetravalent dengue-yellow fever 17D chimeric virus
vaccine (CYD-TDV) completed a phase III clinical trials, conducted
in ﬁve countries in Asia. The vaccine demonstrated 56.5% over-
all efﬁcacy against dengue, but only 35%, efﬁcacy against DENV-2.
Additional options for candidate dengue vaccines are clearly still
needed.
We developed a novel dengue nanovaccine composed of the
UVI-DENV antigen loaded on CS/BCG-NPs. UVI-DENV retained
intact epitopes that are necessary to generate humoral and cellu-
lar immune responses. Psoralen and UV-inactivation have already
been used to develop an inactivated DENV-1 vaccine currently in
pre-clinical testing [7]. NPs were chosen as the vaccine delivery
system due to their small size and fast up-take by APCs, probably
the result of the positive surface charge of NPs, which increases NP
adhesion to cell surfaces. NPs have been shown to activate innate
immunity by inducing the productions of various cytokines, in par-
ticular IFN- [46] and expression of CD80, CD86 and HLA-DR in
dendritic cells as well as the secretion of IL-1, IL-6 and IL-12p70
[47].Several cytokines induced by adjuvant and DNV play important
roles in response to DENV infection, including IL-1, IL-2 [48], IL-10
[49], IL-17 [50], IFN- [51] and other chemokines [52]. IL-17 has the
ability to induce production of other proinﬂammatory cytokines
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n response to Mycobacterium tuberculosis [53] and viral infections
ike DENV [54]. IL-17 is secreted from Th17 cells and other immune
ells such as NK cells, NKT cells and macrophages. IL-12p40 and
L-12p70 play an important role in induction of Th1 responses
n response to DENV infection. Surprisingly, in our experiments,
djuvant alone induced higher IL-17, IL-12p40 and IL-12p70 pro-
uctions than DNV did, even though the amount of adjuvant used
as similar. It is possible that UVI-DENV present in the DNV delayed
r accelerated the production of those three cytokines. This may
e explained by the differences in the size of the vaccine particle;
here the DNV has a diameter of 372 nm,  and the adjuvant (com-
osed of the BCG-CWC captured in the CS-NP) with a diameter of
nly 299 nm (data not published). The smaller particle size of the
djuvant, combined with a higher positive surface charge (mea-
ured by zetasizer and not published here) may  have increased
he mobility and cell internalization of the adjuvant. It may  also
ake the adjuvant more available to different cytokine-secreting
ell types. Additionally, UVI-DENV and BCG-CWC, both compet-
ng for surface space in the NPs may  hindrance each other’s access
o the targeted cells. DNV also induced secretion of various other
mmune mediators like TNF-, an endogenous pyrogen normally
ound during acute DENV infection [55]; IFN- and IL-2, effectors of
iral clearance and T cell proliferation; IL-4 and IL-5, involved in B
ell differentiation into plasma cells; and chemokines like RANTES,
CP-1 and MIP-1 which are associated with cell migration, pro-
iferation and activation of immune cells [56,57].
The role of CMI  in protection against dengue disease remains
nclear, but inclusion of T-cell epitopes in the vaccine has been
hown to improve viral clearance in murine [58] and NHP models
59]. While T-cell responses may  play a critical role in viral clear-
nce during primary infections, low afﬁnity interactions between
pitopes and T-cells during secondary infections may  contribute
o the pathology of the disease [60]. Inactivated vaccines tend to
nduce little or no CMI  [61]. However, with the help of CS/BCG-NPs,
n adjuvant, our DNV was able to induce signiﬁcant CMI responses.
Humoral immunity is essential for protection against DENV
nfection and infection with one DENV serotype normally generates
ong lasting antibodies against such serotype. However, heterotypic
ENV protection is short-lived. In this study, DNV-immunized
ice secreted cross reactivity anti-DENV-1,-3 and -4 antibodies
s determined by ELISA test, demonstrating that DNV was  highly
mmunogenic. These ﬁndings are in agreement with a prior study
howing that long term humoral immunity was achieved in Swiss
lbino mice inoculated with three doses of Psoralen-inactivated
ENV-1 [7]. DNV induced secretion of anti-DENV-2 IgG antibod-
es sooner than what was demonstrated using psoralen-inactivated
ENV-1. This underscores the effect of CS/BCG-NPs, an adjuvant,
n improving the ability of UVI-DENV antigen to stimulate host
mmune responses.
The potential protective properties of DNV in mice were
emonstrated by the similar trends in secretion of NT antibod-
es against DENV2 16681 reference strain, the clinical-isolate
train (00745/10) and the mouse-adapted NGC strain. Nonetheless,
he amino acid sequences on EdIII protein of the clinical-isolate
train differ from reference strain, and this may  account for the
owest NT antibodies generated against this strain. As of today,
RNT assay is the most predictive test for protection against
engue.
In conclusion, our novel DNV stimulated both humoral and
ell-mediated immune responses. High production of NT antibod-
es and stimulation of T-cells support the potential use of DNV
s a dengue vaccine candidate. This study is the ﬁrst step of
NV development. Several questions remain to be elucidated. The
ltimate goal of this study is to develop a safe and effective tetrava-
ent DNV with the capability to protect against all four dengue
erotypes.
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